Immunic Therapeutics has closed a private placement that could provide up to $400 million to support the company’s Phase 3 clinical program of vidofludimus calcium in multiple sclerosis (MS) and help fund its transition into a commercial-stage company as it prepares for potential regulatory approval of the…
vidofludimus calcium
Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium can target key mechanisms underlying disease progression in multiple sclerosis (MS), including acute and chronic inflammation, as well as Epstein-Barr virus (EBV) reactivation, according to new trial data. The Phase 2 CALLIPER trial (NCT05054140)Â investigated vidofludimus calcium against a…
Recommended Posts
- Over 70% of MS patients in rehab take 5 or more medications, study finds
- New research project to explore how women with MS experience menopause
- MS progression is unpredictable, but I’m learning to adapt
- Lucid-MS moves toward clinical trial in US that will enroll MS patients
- With MS, movement can be one of the greatest teachers